Close Menu

NEW YORK (GenomeWeb) — Australian molecular diagnostics firm Genetic Technologies announced on Wednesday that it has signed a A$20 million ($14.9 million) equity placement agreement with Melbourne-based investment management firm Kentgrove Capital.

Under the terms of the deal, Kentgrove may make a series of individual equity investments in Genetic Technologies of up to A$1 million each — or more by mutual agreement — over the next 20 months, totaling up to A$20 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.